Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-13
2005-12-13
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C514S029000, C514S034000, C514S037000, C514S041000, C424S649000, C436S063000, C436S086000, C436S087000
Reexamination Certificate
active
06974798
ABSTRACT:
Compositions and methods are provided for prophylactic or therapeutic treatment of balance impairments involving neuronal damage, loss, or degeneration, preferably of vestibular ganglion neurons, in an animal by administration of an effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5.
REFERENCES:
patent: 6121235 (2000-09-01), Gao
patent: 6429196 (2002-08-01), Gao
Anniko et al., “Cisplatin: Evaluation of its Ototoxic Potential”Am. J. Otolaryngol.7:276-293 (1986).
Apfel et al., “Nerve Growth Factor Prevents Toxic Neuropathy in Mice”Annals of Neurology29(1):87-90, (Jan. 1991).
Ard et al., “Trophic Interactions Between the Cochleovestibular Ganglion of the Chick Embryo and its Synaptic Targets in Culture”Neuroscience16(1):151-170 (1985).
Au et al., “Aminoglycoside Antibiotics Preferentially Increase Permeability in Phosphoinositide-containing membranes: a Study with Carboxyfluorescein in Liposomes”Biochimica et Biophysica Acta902:80-86 (1987).
Baird et al., “Cerebellar Target Neurons Provide a Stop Signal for Afferent Neurite Extension in vitro”The Journal of Neuroscience12(2):619-634 (Feb. 1992).
Barbacid, “The Trk Family of Neurotrophin Receptors: Molecular Characterization and Oncogenic Activation in Human Tumors”Molecular Genetics of Nervous System Tumorspps. 123-136 (1993).
Barde et al., “Purification of a New Neurotrophic Factor From Mammalian Brain”EMBO Journal1(5):549-553 (1982).
Bareggi et al., “Gentamicin Ototoxicity: Histological and Ultrastructural Alterations After Transtympanic Administration”Pharmacological Research22(5):635-644 (1990).
Barker et al., “Disruption of NGF Binding to the Low Affinity Neurotrophin Receptor p75LNTRReduces NGF Binding to TrkA on PC12 Cells”Neuron13:203-215 (1994).
Berggren et al., “Intermediate Filament Proteins in the Embryonic Inner Ear of Mice Under Normal Conditions and After Exposure to Ototoxic Drugs”Acta Otolaryngol109:57-65 (1990).
Berkemeier et al., “Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB”Neuron7:857-866 (Nov. 1991).
Boettcher et al., “Concentration of Salicylate in Serum and Perilymph of the Chinchilla”Arch. Otoloaryngol Head Neck Surg.116:681-684 (1990).
Boettcher et al., “Effects of Sodium Salicylate on Evoked-response Measures of Hearing”Hearing Research42:129-142 (1989).
Boettcher et al., “Salicylate Ototoxicity: Review and Synthesis”Am. J. Otoloaryngol.12:33-47 (1991).
Carenza et al., “Peripheral Neuropathy and Ototoxicity of Diclorodiamineplatinum: Instrumental Evaluation”Gynecologic Oncology25:244-249 (1986).
Chao, “Gene Transfer and Molecular Cloning of the Human NGF Receptor”Science232:518-521 (1986).
Chao, “Growth Factor Signaling: Where is the Specificity?”Cell68:995-997 (Mar. 20, 1992).
Clary et al., “An Alternatively Spliced Form of the Nerve Growth Factor Receptor TrkA Confers an Enhanced Response to Neurotrophin 3”Proc. Natl. Acad. Sci. USA91:11133-11137 (1994).
Clary et al., “TrkA Cross-linking Mimics Neuronal Responses to Nerve Growth Factor”Molecular Biology of the Cell5:549-563 (1994).
Cohen et al., “Neurotrophin-4/5 (NT-4/5) Increases Adult Rat Retinal Ganglion Cell Survival and Neurite Outgrowth in vitro”Journal of Neurobiology25(8):953-959 (1994).
Cordon-Cardo et al., “The trk Tyrosine Protein Kinase Mediates the Mitogenic Properties of Nerve Growth Factor and Neurotrophin-3”Cell66:173-183 (Jul. 12, 1991).
Corwin et al., “Auditory Hair Cells: Structure, Function, Development, and Regeneration”Annu. Rev. Neuroscience14:301-333 (1991).
Cotanche et al., “Regeneration of Hair Cells in the Vestibulocohlear System of Birds and Mammals”Current Opinion in Neurobiology4:509-514 (1994).
Davies et al., “Different Factors From the Central Nervous System and Periphery Regulate the Survival of Sensory Neurones”Nature319:497-499 (1986).
Davies et al., “Neurotrophin-4/5 Is a Mammalian-specific Survival Factor for Distinct Populations of Sensory Neurons”J. Neuroscience13(11):4961-4967 (Nov. 1993).
Davies et al., “p75-Deficient Trigeminal Sensory Neurons Have an Altered Response to NGF but Not to Other Neurotrophins”Neuron11:565-574 (Oct. 1993).
De Moura, “Inner Ear Pathology in Acoustic Neurinoma”Arch. Otolaryng.85:21-29 (125-133) (Feb. 1967).
Dublin, “Anatomic Principles With Some Functional and General Pathologic Applications”Fundamentals of Sensorineural Auditory Pathology(Chapter 3), Springfield, Illinois: Charles C. Thomas pps. 18-103 (1976).
Duckert et al., “Morphological Correlates of Functional Recovery in the Chicken Inner Ear After Gentamycin Treatment”The Journal of Comparitive Neurology331:75-96 (1993).
Ernfors et al., “Function of the Neurotrophins in the Auditory and Vestibular Systems: Analysis of BDNF and NT-3 Gene Knockout Mice”ARO Abstracts(abstract 759) pps. 190 (1995).
Ernfors et al., “Mice Lacking Brain-derived Neurotrophic Factor Develop with Sensory Deficits”Nature368:147-149 (Mar. 10, 1994).
Ernfors et al., “Molecular Cloning and Neurotrophic Activities of a Protein With Structural Similarities to Nerve Growth Factor: Developmental and Topographical expression in the brain”Proc. Natl. Acad. Sci. USA87:5454-5458 (Jul. 1990).
Escandon et al., “Regulation of Neurotrophin Receptor Expression During Embryonic and Postnatal Development”The Journal of Neuroscience14(4):2054-2068 (Apr. 1994).
Falbe-Hansen, “Clinical and Experimental Histological Studies on Effects of Salicylate and Quinine on the Ear”Acta Otolaryng. Supp.44:1-216 (1941).
Farinas et al., “Severe Sensory and Sympathetic Deficits in Mice Lacking Neurotrophin-3”Nature369:658-661 (Jun. 23, 1994).
Fischer et al., “Reversal of Spatial Memory Impairments in Aged Rats by Nerve Growth Factor and Neurotrophins 3 and 4/5 but not by Brain-Derived Neurotrophic Factor”Proc. Natl. Acad. Sci. USA91:8607-8611 (Aug. 1994).
Forge et al., “Ultrastructural Evidence for Hair Cell Regeneration in the Mammalian Inner Ear”Science259:1616-1619 (Mar. 12, 1993).
Fritzsch, “Mice Homozygous for a Non-functional trk-B Receptor Lack Selectively in th Innervation of Semicircular Canals”ARO Abstracts(Abstract 760) pps. 190 (1995).
Furley et al., “The Axonal Glycoprotein TAG-1 is an Immunoglobulin Superfamily Member with Neurite Outgrowth-Promoting Activity”Cell61:157-170 (Apr. 6, 1990).
Gao et al., “Cerebellar Granule Cell Neurogenesis is Regulated by Cell-Cell Interactions in Vitro”Neuron6:705-715 (May 1991).
Gao et al., “Neurotrophin-3 Reverses Experimental Cisplatin-induced Peripheral Sensory Neuropathy”Annals of Neurology38(1):30-37 (Jul. 1995).
Gao et al., “Neurotrophin-4/5 (NT-4/5) and Brain-Derived Neurotrophic Factor (BDNF) Act at Later Stages of Cerebellar Granule Cell Differentiation”The Journal of Neuroscience15(4):2656-2667 (Apr. 1995).
Garner et al., “Isoforms of the Avian TrkC Receptor: A Novel Kinase Insertion Dissociates Transformation and Process Outgrowth From Survival”Neuron13:457-472 (1994).
Gotz et al., “Neurotrophin-6 is a New Member of the Nerve Growth Factor Family”Nature372:266-269 (1994).
Gotz et al., “Production and Characterization of Recombinant Mouse Neurotrophin-3”European Journal of Biochemistry204:745-749 (1992).
Guild et al., “Correlations of Differences in the Density of Innervation of the Organ of Corti with Differences in the Acuity of Hearing. Including Evidence as to the Location in the Human Cochlea of the Receptors for Certain Tones”Acta Oto-Laryngologica.Holmgren vol. XV:269-308 (1931).
Jones et al., “Molecular Cloning
Agarwal Atulya R.
Dreger Ginger R.
Fox James A.
Genentech Inc.
Henley III Raymond J.
LandOfFree
Treatment of balance impairments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of balance impairments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of balance impairments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3506340